How did you see the quarterly results of Sanofi India Ltd for Mar-22 quarter?
Answer
Answer
Global pharma major, Sanofi India, sales for Mar-22 quarter fell -2.5% at Rs.707 crore for the Mar-22 quarter even as sequential sales were higher by 2.8%. Mar-22 was the first quarter for Sanofi India as it follows the calendar year. During the fiscal, Sanofi board had approved transfer of tangible and intangible assets pertaining to the distribution unit of Soframycin and Sofradex to Encube Ethicals Private Limited. The deal was consummated in Jan-22.
Sanofi India
Rs in Crore
Mar-22
Mar-21
YOY
Dec-21
QOQ
Total Income (Rs cr)
₹ 707.00
₹ 725.10
-2.50%
₹ 687.90
2.78%
Net Profit (Rs cr)
₹ 238.40
₹ 145.90
63.40%
₹ 90.40
163.72%
Diluted EPS (Rs)
₹ 103.51
₹ 63.35
₹ 39.25
Net Margins
33.72%
20.12%
13.14%
Let us turn to the profit performance. Net profits for Mar-22 first quarter were up 63.4% at Rs.238.4cr. However, the sharp spike in profits was boosted by the exceptional gains of Rs.118.10 crore arising from sale of distribution business of Soframycin and Sofradex. The entire consideration has been received by the company. Net margins stood at 33.72% in Mar-22 quarter against 20.12% in Mar-21. QOQ, the NPM was higher compared to 13.14%.